Aethlon Medical, Inc. (NASDAQ:AEMD – Get Rating)’s share price passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $1.25 and traded as high as $1.39. Aethlon Medical shares last traded at $1.36, with a volume of 1,465,208 shares changing hands.
Wall Street Analyst Weigh In
Separately, StockNews.com upgraded shares of Aethlon Medical to a “sell” rating in a report on Friday, August 12th.
Aethlon Medical Stock Performance
The stock has a market cap of $22.63 million, a price-to-earnings ratio of -1.86 and a beta of 0.77. The company’s 50 day simple moving average is $1.16 and its two-hundred day simple moving average is $1.25.
Aethlon Medical (NASDAQ:AEMD – Get Rating) last announced its quarterly earnings data on Tuesday, June 28th. The medical equipment provider reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.13). The business had revenue of $0.01 million during the quarter, compared to analyst estimates of $1.02 million. Aethlon Medical had a negative net margin of 3,542.86% and a negative return on equity of 59.57%. On average, equities research analysts predict that Aethlon Medical, Inc. will post 0.56 earnings per share for the current fiscal year.
Institutional Trading of Aethlon Medical
Several institutional investors have recently added to or reduced their stakes in the company. NTB Financial Corp acquired a new stake in Aethlon Medical during the 4th quarter valued at approximately $32,000. Natixis bought a new position in shares of Aethlon Medical during the 2nd quarter worth $28,000. Finally, Renaissance Technologies LLC grew its position in shares of Aethlon Medical by 11.6% in the first quarter. Renaissance Technologies LLC now owns 270,297 shares of the medical equipment provider’s stock valued at $395,000 after purchasing an additional 28,097 shares in the last quarter. 10.58% of the stock is currently owned by institutional investors.
Aethlon Medical Company Profile
Aethlon Medical, Inc, a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system, including removal of COVID-19 virus, associated variants, and related exosomes.
See Also
Receive News & Ratings for Aethlon Medical Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Aethlon Medical and related companies with MarketBeat.com’s FREE daily email newsletter.
Read More: Aethlon Medical (NASDAQ:AEMD) Shares Cross Above 200 Day Moving Average of $1.25